4'-hydroxydiclofenac
InChIKey: KGVXVPRLBMWZLG-UHFFFAOYSA-N

Need public description.

Compound information managed by NaPDI


None listed

None listed


None listed
ID Subject of Study Study Name Name Type Overall Effect Enzymes Transporters Object Object Metabolite Precipitant
NPDI-bOmVTQ Kratom (Mitragyna speciosa) Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations Screening of mitragynine as inhibitors of CYP2C9 activity in HLM In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac mitragynine
NPDI-2KGgbg Green tea (Camellia sinensis) Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450 Percent inhibition of CYP2C9 by epicatechin gallate In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac epicatechin gallate
NPDI-38xlLg Green tea (Camellia sinensis) Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450 In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac epigallocatechin gallate
NPDI-Jb4JFA Cannabis (Cannabis sativa) Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. iHLM: THC-diclofenac In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac delta-9-tetrahydrocannabinol
NPDI-Fqa3JA Cannabis (Cannabis sativa) Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. iHLM: CBD-diclofenac In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac cannabidiol
NPDI-V1SemA Cannabis (Cannabis sativa) Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. iHLM: CBN-diclofenac In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac cannabinol
NPDI-bM6NOQ Cannabis (Cannabis sativa) Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. rCYP2C9: THC-diclofenac In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac delta-9-tetrahydrocannabinol
NPDI-LKS7Ow Cannabis (Cannabis sativa) Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. rCYP2C9: CBD-diclofenac In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac cannabidiol
NPDI-KqafWg Cannabis (Cannabis sativa) Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. rCYP2C9: CBN-diclofenac In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac cannabinol
NPDI--K80vw Goldenseal (Hydrastis canadensis) Human Cytochrome P450 Inhibition and Metabolic-Intermediate Complex Formation By Goldenseal Extract and Its Methylenedioxyphenyl Components 2C9 Inhibition by GS Extract In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac goldenseal root extract
NPDI-iSHQYQ Goldenseal (Hydrastis canadensis) Human Cytochrome P450 Inhibition and Metabolic-Intermediate Complex Formation By Goldenseal Extract and Its Methylenedioxyphenyl Components 2C9 Inhibition by Berberine In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac berberine
NPDI-3M10oA Goldenseal (Hydrastis canadensis) Human Cytochrome P450 Inhibition and Metabolic-Intermediate Complex Formation By Goldenseal Extract and Its Methylenedioxyphenyl Components 2C9 Inhibition by (+) Hydrastine In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac hydrastine
NPDI-wdarow Goldenseal (Hydrastis canadensis) Human Cytochrome P450 Inhibition and Metabolic-Intermediate Complex Formation By Goldenseal Extract and Its Methylenedioxyphenyl Components 2C9 Inhibition by (-) Hydrastine In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac (-)-beta-hydrastine
NPDI-4HfEdA Kratom (Mitragyna speciosa) Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids Inhibition of Paynantheine for CYP2C9 In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac paynantheine
NPDI-DLH-JQ Kratom (Mitragyna speciosa) Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids Weak Inhibition of 7-hydroxymitragynine for CYP2C9 In Vitro Enzyme Inhibition negative — In Vitro Enzyme Negligible Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac 7-hydroxymitragynine
NPDI-bXPXRQ Kratom (Mitragyna speciosa) Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids Inhibition of Corynantheidine for CYP2C9 In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac corynantheidine
NPDI-t32_Ig Kratom (Mitragyna speciosa) Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids Control Positive Inhibition for CYP2C9 In Vitro Enzyme Inhibition (Control experiment) positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac sulfaphenazole
NPDI-0hNq0Q Kratom (Mitragyna speciosa) Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids Weak Inhibition of Mitragynine for CYP2C9 In Vitro Enzyme Inhibition negative — In Vitro Enzyme Negligible Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac mitragynine
NPDI-xK3lmw Kratom (Mitragyna speciosa) Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations IC50 shift determination for mitragynine towards CYP2C9 activity in HLM without NADPH In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac mitragynine
NPDI-71pBaQ Kratom (Mitragyna speciosa) Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations Screening of kratom extracts as inhibitors of CYP2C9 activity in HLM In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac methanolic extract of kratom
NPDI-Zvn2gg Kratom (Mitragyna speciosa) Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids Weak Inhibition of Speciociliatine for CYP2C9 In Vitro Enzyme Inhibition negative — In Vitro Enzyme Negligible Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac speciociliatine
NPDI-Xrn4xQ Kratom (Mitragyna speciosa) Refined Prediction of Pharmacokinetic Kratom-Drug Interactions: Time-Dependent Inhibition Considerations IC50 shift determination for mitragynine towards CYP2C9 activity in HLM with NADPH In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac mitragynine
NPDI-sN1pZA Kratom (Mitragyna speciosa) Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids Weak Inhibition of Speciogynine for CYP2C9 In Vitro Enzyme Inhibition negative — In Vitro Enzyme Negligible Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac speciogynine
NPDI-gvjqdw Cannabis (Cannabis sativa) Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450 THC Inhibition of CYP2C9 In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac delta-9-tetrahydrocannabinol
NPDI-IhJ2pQ Cannabis (Cannabis sativa) Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450 CBD Inhibition of CYP2C9 In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac cannabidiol
NPDI-KEwGCg Cannabis (Cannabis sativa) Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450 11-OH-THC Inhibition of CYP2C9 In Vitro Enzyme Inhibition positive — In Vitro Enzyme Inhibition
  • CYP2C9
diclofenac 4'-hydroxydiclofenac 11-hydroxy-delta-9-tetrahydrocannabinol

Compound information from external resources

Resource Identifier
Google search KGVXVPRLBMWZLG-UHFFFAOYSA-N